Oxcarbazepine Articles
Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal
27 January 2010
Supernus begins Ph III Epliga epilepsy trial
12 January 2009
Anti-epileptics to get suicide warnings in USA
22 December 2008
UCB raises guidance for 2008 above consensus
24 December 2007
FDA approves first Trileptal generics
15 October 2007
JPMA issues guidelines for research tool patent
30 January 2006
UK NICE OKs Novartis' Gleevec as first-line GIST management, also views epilepsy care
8 November 2004
UK NICE guidance on insomnia drugs
10 May 2004
Pfizer continues to dominate neurology drug market
29 March 2004
UK NICE backs newer antiepileptics
29 March 2004
Novartis' Trileptal gets new use OKed in USA
18 August 2003
Trileptal approvable for children in USA
7 January 2002
Trileptal approvable for children in USA
14 December 2001
Novartis' oral Trileptal solution approved in EU
21 August 2001
FDA approves Novartis' Trileptal oral solution
7 June 2001
Novartis puts in solid 1st-half performance
21 August 2000
Novartis says 25% chance Zelmac NDA will not be accepted
22 February 2000
Novartis' Trileptal backed for epilepsy
19 January 2000
Novartis' Trileptal cleared in EU
9 December 1999
Novartis Trileptal approvable in USA; firm building broad franchise in
30 September 1999
Novartis Files For Trileptal In USA
6 October 1998
Epilepsy Market Sees Strong Growth
29 July 1997
Malaysian Drug Regulation Update
1 July 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Higher-Priced Drugs Set To Expand Epilepsy Market
12 February 1996
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
Ciba Reveals Pipeline With Broad Reach
17 April 1995
STRUCTURAL CHANGES AT CIBA
22 November 1993
THE DAWN OF A NEW ERA FOR EPILEPSY
27 September 1993
NEW HOPES FOR EPILEPSY TREATMENT
12 July 1993
ANALYSTS ASSESS CIBA'S PHARMA PROSPECTS
9 November 1992
Showing 1-50 of 50 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
